Globe Newswire

Luxembourg – 10 May 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a large1 contract by Turkish Petroleum Offshore Technology Center AS (TP-OTC) relating to the Sakarya field development in the Black Sea, offshore Türkiye. The award will be booked in backlog in Q2 2024.

An initial contract was awarded in May 2023 to a consortium including SLB, Subsea Integration Alliance2 and Saipem for the engineering, procurement, construction and... (continue reading...)

On May 22th 2024 at 9:00 AM CEO of AB “Novaturas” Mr. Kristijonas Kaikaris and CFO Mr. Vaidrius Verikas will present the Company’s consolidated financial results for the first quarter of 2024 to investors.

We kindly ask to register for the webinar using the link below:

https://nasdaq.zoom.us/webinar/register/WN_9f5HjXmfQt210z9xIfpBjQ

CFO Vaidrius Verikas +370 646 43758

AB Amber Grid, legal entity code: 303090867. Address: Laisvės ave. 10, LT-04215 Vilnius, Lithuania.

Amber Grid delivers results for the 1st quarter of 2024 prepared according to the International Financial Reporting Standards:

• Revenue for the 1st quarter of 2024 EUR 20.6 million (the 1st quarter of 2023 EUR 25.5 million);• Net profit for the 1st quarter of 2024 EUR 4.0 million (the 1st quarter of 2023 EUR 1.8 million);• EBITDA (earnings before interest,... (continue reading...)

PISCATAWAY, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- UK Satellite Applications Catapult’s Harwell Campus will be the site of the second PlugFest of the Digital Intermediate Frequency Interoperability Consortium (DIFI). This first-ever DIFI event in Europe is being organized by founding member ETL Systems. The PlugFest, which will include companies testing digital operability of ground segment technology using the DIFI Standard, begins on Monday June 17 and will run... (continue reading...)

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1:

• 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs)

• 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond

• Best responder duration of response was 28.0 months with response ongoing as of May 10, 2024
• U.S. prevalence of... (continue reading...)